XtalPi Holdings Ltd

HKSE 2228.HK

XtalPi Holdings Ltd Gross Profit Margin for the year ending December 31, 2023: 27.66%

XtalPi Holdings Ltd Gross Profit Margin is 27.66% for the year ending December 31, 2023, a -44.19% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.
  • XtalPi Holdings Ltd Gross Profit Margin for the year ending December 31, 2022 was 49.56%, a -5.07% change year over year.
  • XtalPi Holdings Ltd Gross Profit Margin for the year ending December 31, 2021 was 52.21%.
Key data
Date Gross Profit Margin Operating Income Margin EBT Margin Net Income Margin
Market news
SV Wall Street
HKSE: 2228.HK

XtalPi Holdings Ltd

CEO Dr. Jian Ma Ph.D.
IPO Date June 21, 2010
Location China
Headquarters The third floor of the second phase of the International Biomedical Industrial Park, No. 2 Hongliu Road, Futian District
Employees 760
Sector Health Care
Industries
Pharmaceuticals Biotechnology Chemicals & Advanced Materials
Description

XtalPi Holdings Limited, an investment holding company, provides drug discovery and intelligent automation solutions in China, the United States, Europe, South Korea, and Japan. The company's drug discovery solutions cover the whole drug discovery and research process, including target validation, hit identification, lead generation, lead optimization, and PCC nomination covering various modalities, which comprise small molecules, antibodies, peptides, ADC, and PROTAC. Its intelligent automation solutions focus on AI- and automation-enabled novel drug and materials discovery and research. The company was formerly known as QuantumPharm Inc. and changed its name to XtalPi Holdings Limited in December 2024. XtalPi Holdings Limited was founded in 2015 and is headquartered in Shenzhen, China.

StockViz Staff

February 5, 2025

Any question? Send us an email